Activating transcription factor-2 in survival mechanisms in head and neck carcinoma cells

Head and Neck

Volumn 33, Issue 11, 2011, Pages 1586-1599

  Duffey, Dianne ^a   Dolgilevich, Svetlana ^b   Razzouk, Sleiman ^c   Li, Lina ^a   Green, Ross ^c   Gorti, Goutham Krishna ^c  

^a YALE UNIVERSITY   (United States)

^b College of Dental Medicine ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; ATF2; chemoresistance; cisplatin; IL 8

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CISPLATIN; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; CYTOKINES; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054048837     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21648     Document Type: Article

References (35)

1. Kim SJ, Wagner S, Liu F, O'Reilly MA, Robbins PD, Green MR,. Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature 1992; 358: 331-334.
2. Bhoumik A, Huang TG, Ivanov V, et al. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest 2002; 110: 643-650. (Pubitemid 34988788)
3. Bhoumik A, Lopez-Bergami P, Ronai Z,. ATF2 on the double-activating transcription factor and DNA damage response protein. Pigment Cell Res 2007; 20: 498-506. (Pubitemid 47568834)
4. Li XY, Green MR,. Intramolecular inhibition of activating transcription factor-2 function by its DNA-binding domain. Genes Dev 1996; 10: 517-527. (Pubitemid 26091764)
5. Livingstone C, Patel G, Jones N,. ATF-2 contains a phosphorylation- dependent transcriptional activation domain. EMBO J 1995; 14: 1785-1797.
6. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P,. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995; 14: 1798-1811.
7. Gupta S, Campbell D, Dérijard B, Davis RJ,. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389-393.
8. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH,. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 1996; 271: 31929-31936. (Pubitemid 26422216)
9. Hai T, Curran T,. Cross-family dimerization of transcription factors Fos/jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A 1991; 88: 3720-3724. (Pubitemid 21916695)
10. Tsai EY, Jain J, Pasavento PA, Rao A, Goldfeld AE,. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/jun and NFATp. Mol Cell Biol 1996; 16: 459-467. (Pubitemid 26029082)
11. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD,. Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. EMBO J 2006; 25: 1058-1069. (Pubitemid 43372119)
12. Bhoumik A, Fichtman B, Derossi C, et al. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A 2008; 105: 1674-1679. (Pubitemid 351346573)
13. Maekawa T, Shinagawa T, Sano Y, et al. Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol 2007; 27: 1730-1744.
14. Breitwieser W, Lyons S, Flenniken AM, et al. Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev 2007; 21: 2069-2082. (Pubitemid 47267292)
15. Bhoumik A, Ivanov V, Ronai Z,. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001; 7: 331-342. (Pubitemid 32183037)
16. Bhoumik A, Gangi L, Ronai Z,. Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 2004; 64: 8222-8230. (Pubitemid 39491759)
17. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003; 63: 8103-8107. (Pubitemid 37549453)
18. Crowe DL, Shemirani B,. The transcription factor ATF-2 inhibits extracellular signal regulated kinase expression and proliferation of human cancer cells. Anticancer Res 2000; 20: 2945-2949.
19. Henkels KM, Turchi JJ,. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999; 59: 3077-3083. (Pubitemid 29316005)
20. Bauer JA, Kumar B, Cordell KG, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69 (2 Supplement): S106-S108. (Pubitemid 47369403)
21. Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001; 7: 435-442. (Pubitemid 32183050)
22. Wilson C, Purcell C, Seaton A, et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008; 327: 746-759.
23. Ossowski L, Reich E,. Experimental model for quantitative study of metastasis. Cancer Res 1980; 40: 2300-2309. (Pubitemid 10082242)
24. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 3468-3474. (Pubitemid 29334510)
25. Kato T, Duffey D, Ondrey FG, et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 2000; 22: 748-759.
26. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26: 119-129. (Pubitemid 29480441)
27. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Nat Acad Sci U S A 2003; 100: 4138-4143. (Pubitemid 36418170)
28. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63: 1400-1412. (Pubitemid 41628035)
29. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA,; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654. (Pubitemid 46211507)
30. Sánchez-Perez I, Murguía JR, Perona R,. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998; 16: 533-540. (Pubitemid 28062081)
31. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99: 538-548. (Pubitemid 34461606)
32. Agelopoulos M, Thanos D,. Epigenetic determination of a cell-specific gene expression program by ATF-2 and the histone variant macroH2A. EMBO J 2006; 25: 4843-4853. (Pubitemid 44607029)
33. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS,. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999; 274: 16085-16096.
34. Abdollahi T, Robertson NM, Abdollahi A, Litwack G,. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Apoptosis 2005; 10: 1383-1393. (Pubitemid 43117683)
35. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ,. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7: 2649-2661.